TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06111352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralidoxime
Description: Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement

Intervention type: DRUG
Group type: OTHER
Intervention: Atropine
Description: Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
Study: NCT05310695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - rapid
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - ordinary
Description: NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NSAC - active control
Description: The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
Study: NCT06163391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOT201
Description: intravenous infusion
Study: NCT03987802

Intervention type: DRUG
Intervention: Faster-acting insulin aspart
Description: Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT04918290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm Eye Tape
Description: Eye tape to protect the eye from corneal abrasions during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpore Eye Tape
Description: Eye tape to protect the eye from corneal abrasions during surgery.
Study: NCT05285215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated psychological program (IPP)
Description: Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted.
Study: NCT04699838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide
Study: NCT04620993

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position.

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position.

Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position.

Intervention type: OTHER
Intervention: Evaluation of navıcular drop
Description: The amount of navicular drop of both feet will be measured

Intervention type: OTHER
Intervention: Evaluation of navıcular drop
Description: The amount of navicular drop of both feet will be measured

Intervention type: OTHER
Intervention: Evaluation of navıcular drop
Description: The amount of navicular drop of both feet will be measured

Intervention type: OTHER
Intervention: Evaluation of plantar pressure distrubution
Description: The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.

Intervention type: OTHER
Intervention: Evaluation of plantar pressure distrubution
Description: The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.

Intervention type: OTHER
Intervention: Evaluation of plantar pressure distrubution
Description: The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
Study: NCT04790331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablet
Study: NCT06509243

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tablets Acarizax
Description: sublingual immunotherapy to house dust mites
Study: NCT04699838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib
Study: NCT04620772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide vs placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide vs placebo
Study: NCT06509243

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tablets Acarizax
Description: sublingual immunotherapy to house dust mites

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: dupilumab - biologic therapy for atopic dermatitis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dupilumab
Description: dupilumab - biologic therapy for atopic dermatitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine used in atopic dermatitis
Study: NCT06481605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-REX
Description: The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
Study: NCT04542395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Willingness and Uptake of COVID-19 Testing and Vaccination
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
Study: NCT05424744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Management of Hypertension
Description: Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
Study: NCT05392101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox 360 MG
Description: Deferasirox 360 MG p.o. once daily
Study: NCT05749276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darzalex
Description: DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)
Study: NCT05760651

Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Timed up - and - go test
Description: . The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
Study: NCT05503966

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Modification
Description: The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
Study: NCT05591573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index drink
Description: Fruit flavoured drink with low glycemic index sugar (300 ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycemic index drink
Description: Fruit flavoured drink with high glycemic index sugar (300 ml)
Study: NCT06325644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: The diet intervention will start after all baseline testing is complete

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ketone/Glucose Monitoring
Description: KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CGM/CKM
Description: Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood samples will be collected according to the schedule in Figure 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
Description: Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
Study: NCT05876949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT03
Description: AVT03 will be given as 1 time subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Xgeva (denosumab) will be given as 1 time subcutaneous injection
Study: NCT05357118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suppress Stigma, Support Services
Description: Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
Study: NCT05255796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-piece
Description: Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plate-haptic
Description: Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
Study: NCT06016491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
Study: NCT05908630

Intervention type: OTHER
Intervention: Hypothermia
Description: Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C
Study: NCT04996550

Intervention type: DRUG
Intervention: Carvedilol
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.

Intervention type: DRUG
Intervention: Metoprolol Succinate
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Study: NCT05176795

Intervention type: OTHER
Intervention: Stool sample
Description: Comparaison of the gut microbiota composition

Intervention type: OTHER
Intervention: Stool sample
Description: Comparaison of the gut microbiota composition
Study: NCT05440123

Intervention type: OTHER
Intervention: screening for bronchopulmonary cancer
Description: The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
Study: NCT06059443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mLab App Plus
Description: Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
Study: NCT05228535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk fortifier
Description: Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
Study: NCT06566170

Intervention type: DRUG
Intervention: Donanemab
Description: Administered IV
Study: NCT06150313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)
Description: This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)
Description: This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)
Description: This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
Study: NCT05577481

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: sham iTBS combined with antidepressants
Description: Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iTBS combined with antidepressants
Description: Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.